Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
193.60
+4.53 (+2.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Today 10:38 EDT
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February...
Via
Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48...
Via
Benzinga
Forecasting The Future: 20 Analyst Projections For Biogen
September 23, 2024
Via
Benzinga
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
September 09, 2024
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
Via
Benzinga
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
September 09, 2024
Via
Benzinga
Key Takeaways From Biogen Analyst Ratings
September 04, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Biogen
August 19, 2024
Via
Benzinga
How Is The Market Feeling About Biogen?
August 09, 2024
Via
Benzinga
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
September 09, 2024
Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics...
Via
Benzinga
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
September 04, 2024
Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor function in treatment-naïve infants with spinal muscular atrophy, compared...
Via
Benzinga
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
August 31, 2024
This competitive showdown just saw one of the players hit a couple of bumps.
Via
The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
August 28, 2024
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.
Via
Benzinga
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
August 27, 2024
PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185.
Via
Benzinga
Biogen Earnings Flat; Biotech Giant Raises Guidance
August 01, 2024
Sales slightly topped. Shares edged higher early Thursday.
Via
Investor's Business Daily
The Analyst Verdict: Biogen In The Eyes Of 12 Experts
July 29, 2024
Via
Benzinga
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
August 26, 2024
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed.
Via
Benzinga
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
August 22, 2024
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated...
Via
Benzinga
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
August 11, 2024
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.
Via
The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Apple and Meta had strong results, while AI spending remains robust.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Biogen (BIIB) Q2 2024 Earnings Call Transcript
August 01, 2024
BIIB earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
August 01, 2024
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...
Via
Benzinga
Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales
August 01, 2024
Biogen reported Q2 adjusted EPS of $5.28, surpassing the $4.03 consensus. Sales were $2.47 billion, narrowly beating the $2.38 billion consensus. Notable changes include a 5% drop in multiple sclerosis...
Via
Benzinga
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
August 01, 2024
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...
Via
Benzinga
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
July 29, 2024
Biogen stock has slipped 18% so far this year.
Via
The Motley Fool
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
July 26, 2024
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...
Via
Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
July 26, 2024
Biogen partner Eisai is planning to ask European regulators to re-examine their decision.
Via
Investor's Business Daily
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
July 24, 2024
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.
Via
Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.